코골이 방지 치료 시장 보고서 : 기기 유형, 유통 채널, 지역별(2024-2032년)

The global anti-snoring treatment market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.

Snoring refers to a noisy breathing sound coming through the nose or mouth of an individual, which is caused by the vibration of the soft tissues of the throat. It is medically treated using surgery or continuous positive airway pressure (CPAP), wherein a mask is worn over the nose or mouth and attached to a machine for delivering a constant flow of air into the nostrils. It can also be cured via lifestyle changes, such as maintaining body weight, relieving the nasal obstruction, changing sleep positions, and avoiding alcohol and sedating medications.

Anti-Snoring Treatment Market Trends:

Rising technological advancements in devices that support anti-snoring treatment represent one of the key factors positively influencing the market. Moreover, long-term snoring increases the risk of developing fatigue, heart attacks, hypertension, stroke, type 2 diabetes, and decreased blood oxygen levels. Besides this, loud and frequent snoring is one of the signs of sleep apnea, which is a chronic condition characterized by shallow breaths or pauses in breathing during sleep. This condition can lead to glaucoma, cancer, and cognitive and behavioral disorders. In addition, people with sleep apnea have an increased threat of motor vehicle accidents as it can affect driving fitness. Consequently, there is a rise in the usage of anti-snoring apps, behavioral therapies, dental devices, tongue stabilizing devices (TSD), and mandibular advancing devices (MAD), also known as jaw advancing devices (JAD), to treat snoring, which is fueling the market growth. Furthermore, factors like sedentary lifestyles, unhealthy dietary habits, increasing tobacco and alcohol consumption, and the rising prevalence of sleep disorders among the masses are projected to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-snoring treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on device type and distribution channel.

Breakup by Device Type:

Mandibular Advancement Devices (MAD)

Tongue Stabilizing Devices (TSD)

Continuous Positive Airway Pressure (CPAP) Devices

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Airway Management Inc., Apnea Sciences Corporation, Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., MEDiTAS Ltd., Medtronic plc, Mitsui Chemicals Inc., ResMed Inc., Rotech Healthcare Inc., SomnoMed, The Pure Sleep Company and Tomed GmbH.

Key Questions Answered in This Report

• 1. How big is the global anti-snoring treatment market?
• 2. What is the expected growth rate of the global anti-snoring treatment market during 2024-2032?
• 3. What are the key factors driving the global anti-snoring treatment market?
• 4. What has been the impact of COVID-19 on the global anti-snoring treatment market?
• 5. What is the breakup of the global anti-snoring treatment market based on the device type?
• 6. What is the breakup of the global anti-snoring treatment market based on the distribution channel?
• 7. What are the key regions in the global anti-snoring treatment market?
• 8. Who are the key players/companies in the global anti-snoring treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Anti-Snoring Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Device Type

• 6.1 Mandibular Advancement Devices (MAD)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Tongue Stabilizing Devices (TSD)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Continuous Positive Airway Pressure (CPAP) Devices
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Airway Management Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 Apnea Sciences Corporation
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Fisher & Paykel Healthcare Corporation Limited
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
  • 13.3.4 Koninklijke Philips N.V.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 MEDiTAS Ltd.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 Medtronic plc
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Mitsui Chemicals Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 ResMed Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Rotech Healthcare Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 SomnoMed
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
  • 13.3.11 The Pure Sleep Company
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
  • 13.3.12 Tomed GmbH
    • 13.3.12.1 Company Overview
    • 13.3.12.2 Product Portfolio